FOLFOX chemotherapy (which consists of the anticancer drugs oxaliplatin, 5-fluorouracil, and leucovorin) is a standard treatment for patients with esophageal and/or stomach cancer (esophagogastric cancer). Regorafenib is an anticancer drug that inhibits the growth of the blood vessels that tumors need to grow and spread. It is approved for treating colon cancer and a rare form of digestive cancer called gastrointestinal stromal tumor (GIST), but its use to treat esophagogastric cancer is considered investigational.
Doctors believe that giving FOLFOX with regorafenib may be more effective than giving FOLFOX alone. In this study, researchers are assessing the safety and effectiveness of FOLFOX plus regorafenib in patients with inoperable or metastatic esophagogastric cancer. FOLFOX is given intravenously (by vein), while regorafenib is taken orally (by mouth).